Peptide Statistics 2026
The team at Cernum Biosciences recently analyzed internal purchasing data to better understand which peptides are seeing the highest levels of consumer demand. By examining overall sales distribution across our full catalog of peptides, a clear pattern emerges: a small group of leading compounds dominates interest, while a broader range of niche peptides continues to attract more specialized attention.

The Clear Market Leaders
At the top of the list is GLP-3 RT, which accounts for approximately 34% of total demand. This makes it the single most popular peptide by a wide margin.
Following in second place is GHK-CU, representing about 24% of purchases. This figure includes bundle-adjusted data, where each GHK-CU bundle is counted as five individual units to more accurately reflect real usage and demand. Combined, GLP-3 RT and GHK-CU make up well over half of all peptide purchases—highlighting a strong concentration of interest in these two compounds.
The Second Tier of Demand
Beyond the top two, a second group of peptides shows moderate but consistent popularity. CJC 1295 (no DAC) + Ipamorelin accounts for roughly 10% of demand, while BPC-157 represents around 8%.
Additional peptides such as GLOW 70 and TB500 each contribute just over 4%, indicating steady but more targeted interest compared to the leading compounds.
The Long Tail: Specialized and Emerging Interest
A number of peptides fall into what can be described as a “long tail” of demand—products that are purchased less frequently but still maintain a presence among consumers. These include:
- MT2
- Tesamorelin
- KLOW 80
- MOTS-C
- Ipamorelin (standalone)
Each of these peptides accounts for approximately 2–3% (or slightly less) of total purchases. While individually smaller in share, collectively they represent meaningful diversity in consumer preferences.
The Least Popular Peptides
At the lower end of the spectrum are a handful of peptides with minimal demand. IGF-1 LR3 represents less than 1% of total purchases, while Kisspeptin-10 and CJC-1295 (No DAC) rank as the least popular, each accounting for approximately 0.2% of demand.
What This Means
This data highlights a familiar trend seen across many specialized markets: a few standout products capture the majority of attention, while a wide range of alternatives serve more specific or emerging needs.
For consumers, this provides insight into which peptides are currently most widely used and recognized. For the industry, it underscores where interest is most concentrated—and where future education, research, and product development may evolve.
To learn more about Cernum Biosciences, visit the About Us
Peptide Statistics 2026: 40+ Data Points on Market Growth, Drug Approvals, and Access
GLP-1 medicines alone accounted for about $132 billion, or roughly 14%, of all U.S. prescription drug spending in 2025. The global obesity-medicines market reached $66 billion in 2025, and IQVIA forecasts $92 billion in 2026. At the company level, Eli Lilly and Company reported $22.965 billion in 2025 sales for Mounjaro and $13.542 billion for Zepbound, while Novo Nordisk reported DKK 82.347 billion in obesity-care sales. This article aggregates data from the U.S. Food and Drug Administration, American Society of Health-System Pharmacists, peer-reviewed journals, company filings, NHS England, National Institute for Health and Care Excellence, and the U.S. Department of Health and Human Services Office of Inspector General. Because public vendor summaries disagree sharply on what counts as the peptide market, this article uses observable spending, regulator tallies, and company disclosures as its backbone.
Key Takeaways
- GLP-1 medicines represented about $132 billion and 14% of U.S. prescription drug spending in 2025. Source: ASHP press release
- The global obesity-medicines market reached $66 billion in 2025 and is forecast to hit $92 billion in 2026. Source: IQVIA obesity outlook
- Lilly’s Mounjaro generated $22.965 billion and Zepbound $13.542 billion in 2025 sales. Source: Lilly 2025 results
- Mounjaro and Zepbound accounted for 56% of Lilly’s total 2025 revenue. Source: Lilly 2025 Form 10-K
- Novo reported DKK 82.347 billion in obesity-care sales in 2025 and said the global branded GLP-1 obesity market grew 104% by volume, with Novo holding 59.6% volume share. Source: Novo Nordisk financial performance
- A 2025 peer-reviewed review described nearly 100 approved peptide drugs worldwide and 38 peptide drugs in phase III trials. Source: Signal Transduction and Targeted Therapy
- A 2025 Scientific Data paper assembled 58,583 experimentally validated therapeutic peptides, including 21,130 multifunctional peptides, and recorded 120 approved peptide drugs from PepTherDia. Source: Scientific Data peptide dataset
- By May 2025, GLP-1s accounted for 52% of all diabetes prescription volume, up from 18% in 2020. Source: IQVIA GLP-1 impact
- In Medicare Part D, injectable tirzepatide coverage rose from 26.5% in 2022 Q3 to 92.9% in 2024 Q3, while oral semaglutide rose from 40.3% in 2020 Q3 to 91.8% in 2024 Q3. Source: JAMA Medicare coverage
- The most recent peer-reviewed manufacturing-cost model we found estimated injectable semaglutide could be produced for $0.89 to $4.73 per month, versus lowest observed market prices of $38.21 to $353.74. Source: JAMA cost-based pricing
- The most recent peer-reviewed persistence study we found reported 36.5% overall GLP-1 discontinuation at 12 months, rising to 50.3% among obesity-only users. Source: JAMA discontinuation
- Manufacturing is now a balance-sheet story as much as a science story: Novo said it spent about $2 billion on U.S. manufacturing in 2025 and plans $5.6 billion more through 2028, while Lilly separately announced new U.S. facilities worth more than $6 billion, more than $3.5 billion, and more than $1.2 billion across Alabama, Pennsylvania, and Puerto Rico. Source: Novo Nordisk commercial execution
Commercial Scale and Spending
$66 billion is the clearest high-confidence number for the peptide story right now, even though it comes from the broader obesity-medicines category rather than a perfectly bounded peptide-only market. The reason it matters is straightforward: commercial gravity has shifted toward incretin drugs, and that concentration is now driving everything downstream, from manufacturing investment to payer policy to pipeline strategy. In 2026, the question is no longer whether peptide drugs can scale commercially. The question is how concentrated that scale becomes around a handful of metabolic franchises.
| Statistic | Value | Source |
|---|---|---|
| Global obesity-medicines market | $66 billion in list-price sales in 2025 | IQVIA, obesity outlook |
| Global obesity-medicines market forecast | $92 billion in 2026 | IQVIA, obesity outlook |
| U.S. prescription drug spending | $915.2 billion in 2025, up 12.7% vs. 2024 | ASHP/AJHP (2026) |
| GLP-1 class share of U.S. drug spending | About $132 billion and about 14% of total U.S. prescription drug spending in 2025 | ASHP (2026) |
| Mounjaro full-year sales | $22.965 billion in 2025 | Lilly (2026) |
| Zepbound full-year sales | $13.542 billion in 2025 | Lilly (2026) |
| Mounjaro + Zepbound share of Lilly revenue | 56% of total 2025 revenue | Lilly 10-K (2026) |
| Novo obesity-care sales | DKK 82.347 billion in 2025 | Novo Nordisk (2026) |
A useful commercial footnote is concentration. Novo said the global branded GLP-1 obesity market grew 104% by volume in 2025, and that it still held 59.6% branded volume share. That tells you two things at once: the market is still expanding extremely fast, and it is already competitive enough that share matters.
Semaglutide Sales
Combined Semaglutide Revenue (2023-2024)
| Year | Ozempic Revenue | Wegovy Revenue | Total |
|---|---|---|---|
| 2023 | $13.9B | $4.5B | $18.4B |
| 2024 | $15.5B | $7.8B | $23.3B |
Semaglutide Sales Forecast (2025-2030)
Projected Annual Revenue Growth
| Year | Ozempic Revenue | Wegovy Revenue | Total | Growth Rate |
|---|---|---|---|---|
| 2025 | $16.0B | $10.5B | $26.5B | +14% |
| 2026 | $16.8B | $13.5B | $30.3B | +14% |
| 2027 | $17.0B | $16.0B | $33.0B | +9% |
| 2028 | $16.5B | $18.5B | $35.0B | +6% |
| 2029 | $16.0B | $20.5B | $36.5B | +4% |
| 2030 | $15.0B | $22.0B | $37.0B | +1% |
Source: pharmabusinesshub.com
Approvals and Pipeline
Nearly 100 approved peptide drugs worldwide is the best big-picture count in the recent peer-reviewed literature, but the more important signal is underneath it: approved peptides are spread across several disease areas, while the late-stage pipeline is still large enough to matter. This is why peptide statistics work best when they separate the installed base from the development funnel. The field is broad scientifically, yet selective commercially.
Peptides are becoming legal for broader use
The regulatory and market data below show a clear trend toward wider legal access, growing availability, and increased mainstream adoption.
| Statistic | Value | Source |
|---|---|---|
| Approved peptide drugs worldwide | Nearly 100 | Signal Transduction and Targeted Therapy (2025) |
| Rare-disease indications among peptide drugs approved in the 2014-2024 cohort | 7 | Signal Transduction and Targeted Therapy (2025) |
| Diabetes indications among peptide drugs approved in the 2014-2024 cohort | 5 | Signal Transduction and Targeted Therapy (2025) |
| Cancer indications among peptide drugs approved in the 2014-2024 cohort | 5 | Signal Transduction and Targeted Therapy (2025) |
| Peptide drugs currently in phase III trials | 38 | Signal Transduction and Targeted Therapy (2025) |
| Approved peptide drugs recorded in PepTherDia | 120 | Scientific Data (2025) |
| Experimentally validated therapeutic peptides in the dataset | 58,583 | Scientific Data (2025) |
| Dataset taxonomy | 15 major categories and 47 subcategories | Scientific Data (2025) |
Another current approval signal is pace. The 2026 FDA novel-drug page listed 13 novel drug approvals as of May 1, 2026, including metabolic therapies such as once-weekly insulin icodec-abae and navepegritide. Separately, the FDA approved a higher-dose 7.2 mg Wegovy in March 2026. That does not mean peptide approvals are suddenly flooding the market. It means label expansion and lifecycle management are now as important as first approvals.
A good example of how selective annual novelty remains: the 2026 Pharmaceuticals TIDES harvest paper said the FDA approved 46 novel drugs in 2025, including one peptide and three oligonucleotides. Peptide drugs are clearly established. They are not yet routine.
Adoption and Access
52% of all diabetes prescription volume is the tipping-point number in this article. When a class moves from 18% to 52% of prescription volume in five years, the story is no longer emerging therapy. It is care-pathway redesign. The catch is that adoption is not the same as access. Coverage can rise quickly while prior authorization, phased rollout, or out-of-pocket payment still throttles real-world use.
| Statistic | Value | Source |
|---|---|---|
| GLP-1 share of all diabetes prescription volume | 52% in May 2025, up from 18% in 2020 | IQVIA (2025) |
| Commercial GLP-1 prescription volume | 680,000 in Jan. 2020 to 4.7 million in May 2025 | IQVIA (2025) |
| Medicare GLP-1 prescription volume | 400,000 in Jan. 2020 to 2 million in May 2025 | IQVIA (2025) |
| Share of diabetes patients who had started a GLP-1 therapy | Nearly 25% by early 2025, up from 3% four years earlier | IQVIA (2025) |
| GLP-1 share of first-line diabetes therapy | 23% in 2025; 29% for commercially insured initiators in Q1 2025 and 18% in Medicare | IQVIA (2025) |
| Medicare Part D coverage for injectable tirzepatide | 26.5% in 2022 Q3 to 92.9% in 2024 Q3 | JAMA Network Open (2025) |
| Medicare Part D coverage for oral semaglutide | 40.3% in 2020 Q3 to 91.8% in 2024 Q3 | JAMA Network Open (2025) |
| England obesity rollout capacity | 3.4 million estimated eligible people, but only about 220,000 prioritized in the first 3 years of a 12-year rollout | NICE/NHS England (2024-2025) |
The regional outlier is the U.K. private-pay market. IQVIA wrote that more than 2 million people in the UK were paying out of pocket for anti-obesity medicines as of July 2025, almost seven times the number receiving NHS-funded care. That is a strong signal that patient demand can outrun public reimbursement even in relatively structured health systems.
Pricing and Persistence
Injectable semaglutide’s most recent peer-reviewed cost-based estimate bottoms out at $0.89 per month, while observed market prices in the same paper ran as high as $353.74. That pricing gap is one reason access statistics, compounding statistics, and discontinuation statistics keep clustering together. When an effective therapy is expensive, patients either stop, switch, or seek substitutes. For this section, the best peer-reviewed pricing model and the best peer-reviewed persistence dataset we found were both from 2024, so those rows are labeled as the most recent available peer-reviewed evidence.
| Statistic | Value | Source |
|---|---|---|
| Injectable semaglutide estimated cost-based price vs. lowest observed market price | $0.89-$4.73 per month vs. $38.21-$353.74 per month | JAMA Network Open (2024) |
| Oral semaglutide estimated cost-based price vs. lowest observed market price | $38.62-$72.49 per month vs. $71.15-$643.04 per month | JAMA Network Open (2024) |
| FDA shortage status | Tirzepatide shortage resolved in Dec. 2024; semaglutide shortage resolved in Feb. 2025 after both had been in shortage since 2022 | FDA (2024-2026) |
| Anti-obesity share of compounded GLP-1 market | Approximately 83% | IQVIA compounded GLP-1 market (2025) |
| FDA warning on illegal unapproved GLP-1 products | In Feb. 2026, FDA warned that semaglutide, tirzepatide, and retatrutide products falsely labeled for research purposes were being sold directly to consumers | FDA safety statement (2026) |
| Overall GLP-1 discontinuation at 12 months | 36.5% | JAMA Network Open (2024) |
| GLP-1 discontinuation at 12 months among obesity-only users | 50.3% | JAMA Network Open (2024) |
| Association between out-of-pocket cost and discontinuation | Odds ratio 1.02 for each 1-point increase in OOP cost per 30-day supply | JAMA Network Open (2024) |
The branded manufacturers are responding to the affordability problem, but not solving it. NovoCare advertised Wegovy at $349 per month after introductory fills, with Wegovy HD at $399, while Lilly advertised Zepbound single-dose vials starting at $299 per month for 2.5 mg and $399 for 5 mg. Those prices are materially below prior list-price framing, but they still sit far above peer-reviewed cost-based estimates.
Manufacturing and R&D Infrastructure
This is now a capacity race. Novo said it spent about $2 billion on U.S. manufacturing in 2025 and plans $5.6 billion more through 2028, while Lilly keeps stacking site announcements worth billions of dollars. That tells you something important about peptide statistics in 2026: supply chain numbers have become just as informative as clinical-trial counts. At the same time, peptide synthesis remains technically difficult. A 2026 Nature Chemistry paper found aggregation in essentially half of the sequences in its combined automated-flow peptide-synthesis datasets.
| Statistic | Value | Source |
|---|---|---|
| Novo obesity-care sales growth over the strategic plan period | DKK 6 billion in 2019 to DKK 82 billion in 2025 | Novo Nordisk strategic aspirations |
| Novo U.S. manufacturing investment | Approximately $2 billion in 2025, with a further $5.6 billion planned through 2028 | Novo Nordisk Annual Report 2025 |
| Novo manufacturing network expansion | Three former Catalent fill-finish sites were acquired in 2024 for $11.7 billion and are being integrated into Novo’s network | Novo Nordisk Annual Report 2025 |
| Lilly Alabama API site | More than $6 billion investment; 3,450 manufacturing and construction jobs; site will produce peptide medicines | Lilly Alabama press release (2025) |
| Lilly Pennsylvania injectable site | More than $3.5 billion investment and more than 2,800 jobs for next-generation weight-loss medicines | Lilly Pennsylvania press release (2026) |
| Lilly Puerto Rico oral-medicines expansion | More than $1.2 billion investment; 100 manufacturing jobs and up to 1,000 construction jobs | Lilly Puerto Rico press release (2025) |
| Lilly cumulative capital expansion commitments | More than $50 billion since 2020 | Lilly Pennsylvania press release (2026) |
| Peptide-synthesis aggregation in a 2026 study | 49.9% of combined sequences showed aggregation; aggregation typically occurs 5-15 amino acids from the resin anchoring point | Nature Chemistry (2026) |
There is still a real technical upside to peptides. A 2025 review noted that peptides can have 15 to 60 times higher specific activity per unit mass than antibodies, which is one reason they remain attractive despite synthesis and delivery challenges. But that advantage does not erase the manufacturing bottlenecks. It just explains why companies are willing to spend so aggressively to solve them.
Summary Table
| Statistic | Value | Source |
|---|---|---|
| Global obesity-medicines market, 2025 | $66 billion | IQVIA (2026) |
| Global obesity-medicines market, 2026 forecast | $92 billion | IQVIA (2026) |
| U.S. prescription drug spending, 2025 | $915.2 billion | ASHP/AJHP (2026) |
| GLP-1 share of U.S. prescription drug spending, 2025 | About $132 billion; about 14% of total | ASHP (2026) |
| Mounjaro sales, 2025 | $22.965 billion | Lilly (2026) |
| Zepbound sales, 2025 | $13.542 billion | Lilly (2026) |
| Mounjaro + Zepbound share of Lilly revenue | 56% | Lilly 10-K (2026) |
| Novo obesity-care sales, 2025 | DKK 82.347 billion | Novo Nordisk (2026) |
| Growth of branded GLP-1 obesity market volume, 2025 | 104% | Novo Nordisk (2026) |
| Novo share of branded GLP-1 obesity market volume | 59.6% | Novo Nordisk (2026) |
| Approved peptide drugs worldwide | Nearly 100 | Signal Transduction and Targeted Therapy (2025) |
| Peptide drugs in phase III | 38 | Signal Transduction and Targeted Therapy (2025) |
| Therapeutic peptides in 2025 dataset | 58,583 | Scientific Data (2025) |
| Approved peptide drugs in PepTherDia | 120 | Scientific Data (2025) |
| GLP-1 share of diabetes prescription volume by May 2025 | 52% | IQVIA (2025) |
| Medicare Part D coverage for tirzepatide in 2024 Q3 | 92.9% | JAMA Network Open (2025) |
| Eligible population for tirzepatide in England | 3.4 million | NICE/NHS England (2024-2025) |
| Prioritized England rollout in first 3 years | About 220,000 people | NICE/NHS England (2024-2025) |
| Injectable semaglutide cost-based price | $0.89-$4.73 per month | JAMA Network Open (2024) |
| Overall GLP-1 discontinuation at 12 months | 36.5% | JAMA Network Open (2024) |
| Obesity-only GLP-1 discontinuation at 12 months | 50.3% | JAMA Network Open (2024) |
| Anti-obesity share of compounded GLP-1 market | About 83% | IQVIA compounded GLP-1 market (2025) |
| Novo U.S. manufacturing investment plan | ~$2 billion in 2025 and $5.6 billion more through 2028 | Novo Nordisk Annual Report 2025 |
| Lilly Alabama peptide/API site | >$6 billion | Lilly Alabama press release (2025) |
Methodology and Sources
This article was built to maximize citation durability, not keyword volume. We prioritized regulator pages, government reports, peer-reviewed papers, and company filings over secondary summaries. Where 2026 peer-reviewed data were not available, we labeled 2024 or 2025 figures as the most recent available. Recommended refresh cadence for the published page: quarterly, with immediate updates after major FDA approvals, annual reports, and large payer-policy changes.
- U.S. Food and Drug Administration – Novel Drug Approvals for 2026; content current as of May 1, 2026. source
- FDA – FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide; published March 19, 2026. source
- FDA – GLP-1 shortage and compounding statements; key updates December 19, 2024, February 21, 2025, April 1, 2026, and February 4, 2026. source
- American Society of Health-System Pharmacists / American Journal of Health-System Pharmacy – National Trends in Prescription Drug Expenditures and Projections for 2026; published April 30, 2026. source
- Novo Nordisk – Annual Report 2025 and related annual-report pages; published February 3, 2026. source
- Eli Lilly and Company – Q4/full-year 2025 results and manufacturing press releases; published October 29, 2025, December 9, 2025, January 30, 2026, and February 4, 2026. source
- Lilly – 2025 Form 10-K search result indicating Mounjaro and Zepbound accounted for 56% of revenue; filed March 2026. source
- IQVIA – obesity market outlook, GLP-1 diabetes adoption, compounded GLP-1 market, and U.K. out-of-pocket obesity market materials; published 2025-2026. source
- JAMA Network Open – Estimated Sustainable Cost-Based Prices for Diabetes Medicines; published March 27, 2024. This is the most recent peer-reviewed manufacturing-price model we found for semaglutide. source
- JAMA Network Open – GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes; published in 2024. This is the most recent peer-reviewed persistence dataset we found. source
- JAMA Network Open – Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans; published August 29, 2025. source
- U.S. Department of Health and Human Services Office of Inspector General – Medicare Part D Spending for 10 Selected Diabetes Drugs Totaled $35.8 Billion in 2023; issued February 21, 2025 and posted February 24, 2025. source
- National Institute for Health and Care Excellence and NHS England – tirzepatide obesity guidance and phased rollout documents; published December 23, 2024 and updated in 2025. source
- Scientific Data – A comprehensive dataset of therapeutic peptides on multi-function property and structure information; published July 14, 2025. source
- Signal Transduction and Targeted Therapy – Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines; published in 2025. source
- Nature Chemistry – Amino acid composition drives aggregation during peptide synthesis; published in 2026. source
Open questions and limitations: the cleanest publicly auditable total peptide market size number is still hard to establish because category boundaries vary across vendors, especially when some firms include APIs, synthesis tools, or adjacent obesity medicines. For that reason, the headline numbers in this article lean on observed spending, regulatory counts, company disclosures, and peer-reviewed datasets rather than opaque vendor totals.